Pulse Biosciences (PLSE) is back in focus after reporting a wider quarterly net loss and filing a US$75 million at the market equity offering, as its NANOPULSE-AF Study passes the enrollment midpoint.

The recent NANOPULSE-AF Study milestone and the US$75 million at the market offering come after a powerful run in Pulse Biosciences' stock, with a 30 day share price return of 61.32% and year to date share price return of 216.73%. The 3 year total shareholder return of 448.64% points to momentum that has been building over a longer period.

If this kind of move in Pulse Biosciences has caught your attention, it can be useful to see what else is out there in healthcare related technology. You can use our screener to find other companies developing AI driven healthcare tools via the 43 healthcare AI stocks.

After a move like this in Pulse Biosciences, the real tension is simple. Is the recent surge already pricing in the NANOPULSE-AF progress and fresh capital, or is the current valuation still leaving meaningful upside on the table?

Most Popular Narrative: 38.3% Overvalued

The most followed narrative for Pulse Biosciences pegs fair value at $30.67 per share compared to the last close of $42.41. This creates a sizeable gap that this story tries to justify through growth and margin assumptions.

Analysts are not forecasting that Pulse Biosciences will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Pulse Biosciences's profit margin will increase from 9929.0% below breakeven to the average US Medical Equipment industry of 11.8% in 3 years.

Want to see what is sitting behind that sharp swing in profit margin expectations and the very high future earnings multiple that underpins this fair value story? The narrative leans heavily on rapid revenue expansion, a step change in margins and a rich valuation multiple to balance the math.

Result: Fair Value of $30.67 (OVERVALUED)

However, Pulse Biosciences still carries execution risk, including limited current revenue relative to high quarterly costs and the possibility that clinical or reimbursement setbacks could slow procedure adoption.

Next Steps

Given the mix of enthusiasm and concern around Pulse Biosciences, it makes sense to review the full picture and act before sentiment shifts again. Take a moment to weigh both sides of the story by looking at the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Pulse Biosciences?

If Pulse Biosciences has you thinking more seriously about where to put your money next, do not stop here. Use the tools available and give yourself options.

• Target income first by checking out companies with robust yields and payout histories through the 8 dividend fortresses.
• Focus on resilience by scanning financially sound stocks with strong balance sheets using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for opportunity early by reviewing the screener containing 21 high quality undiscovered gems before the market pays closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.